Pacira BioSciences (PCRX) Current Deferred Revenue (2010 - 2017)

Pacira BioSciences' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $102000.0 for Q4 2017.

• In Q4 2017, Current Deferred Revenue fell 82.86% year-over-year to $102000.0; the TTM figure through Dec 2017 stood at $102000.0 (down 82.86% YoY), while the FY2017 annual figure was $102000.0, down 82.86% from the prior year.
• Current Deferred Revenue was $102000.0 for Q4 2017 at Pacira BioSciences, down from $520000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.4 million in Q2 2014 to a low of $102000.0 in Q4 2017.
• Historically, Current Deferred Revenue has averaged $1.1 million across 5 years, with a median of $1.0 million in 2013.
• The sharpest annual moves came in 2013 and 2014: Current Deferred Revenue slumped 86.56% in 2013, then soared 46.71% in 2014.
• A 5-year view of Current Deferred Revenue shows it stood at $1.0 million in 2013, then soared by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then tumbled by 58.27% to $595000.0 in 2016, then plunged by 82.86% to $102000.0 in 2017.
• The last three Current Deferred Revenue figures came in at $102000.0 (Q4 2017), $520000.0 (Q1 2017), and $595000.0 (Q4 2016), per Business Quant data.